{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:11:59Z","timestamp":1778191919918,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41409-026-02843-y","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:44:21Z","timestamp":1775047461000},"page":"591-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic\/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-7895","authenticated-orcid":false,"given":"Christopher","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-3879","authenticated-orcid":false,"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8589-799X","authenticated-orcid":false,"given":"Gonzalo","family":"Bentolila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-695X","authenticated-orcid":false,"given":"Fernando","family":"Barroso Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-7277","authenticated-orcid":false,"given":"Vaneuza","family":"Funke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-8565","authenticated-orcid":false,"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-0697","authenticated-orcid":false,"given":"Robert","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-3056","authenticated-orcid":false,"given":"Devendra","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9827-287X","authenticated-orcid":false,"given":"Marin","family":"Medjugorac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mufaddal T.","family":"Moonim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-3474","authenticated-orcid":false,"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1229-9931","authenticated-orcid":false,"given":"Micaela","family":"Quarchioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-1402","authenticated-orcid":false,"given":"Daniel H.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0304-5697","authenticated-orcid":false,"given":"Natalia","family":"Aranguiz Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-8817","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-4035","authenticated-orcid":false,"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-4346","authenticated-orcid":false,"given":"Jaroslaw","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-2478","authenticated-orcid":false,"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-5017","authenticated-orcid":false,"given":"Patryk","family":"Sobieralski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2843_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41375-025-02620-8","volume":"39","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Hasserjian RP, Rampal RK. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management. Leukemia. 2025;39:1311\u201324.","journal-title":"Leukemia"},{"key":"2843_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adem\u00e0 V, Fuhrmann I, et al. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood. 2020;136:1851\u201362.","journal-title":"Blood"},{"key":"2843_CR3","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood.2024028000","volume":"145","author":"N Polverelli","year":"2025","unstructured":"Polverelli N, Hern\u00e1ndez-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, et al. Role of allo-HCT in \u201cnonclassical\u201d MPNs and MDS\/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025;145:2561\u201373.","journal-title":"Blood"},{"key":"2843_CR4","doi-asserted-by":"publisher","unstructured":"Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transpl 2025. https:\/\/doi.org\/10.1038\/s41409-025-02701-3.","DOI":"10.1038\/s41409-025-02701-3"},{"key":"2843_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015;125:1857\u201365.","journal-title":"Blood"},{"key":"2843_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2843_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2843_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/ajh.27321","volume":"99","author":"N Szuber","year":"2024","unstructured":"Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Am J Hematol. 2024;99:1360\u201387.","journal-title":"Am J Hematol"},{"key":"2843_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/hematology.2020000130","volume":"2020","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes. Hematol Am Soc Hematol Educ Program. 2020;2020:450\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2843_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/hematology.2020000163","volume":"2020","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Lasho T. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a focused review. Hematol Am Soc Hematol Educ Program. 2020;2020:460\u20134.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2843_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajh.26090","volume":"96","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \u20182021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96:379\u201394.","journal-title":"Am J Hematol"},{"key":"2843_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","volume":"34","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020;34:656\u201361.","journal-title":"Leukemia"},{"key":"2843_CR13","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1038\/s41375-021-01258-6","volume":"35","author":"AA Mangaonkar","year":"2021","unstructured":"Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, et al. Genomic stratification of myelodysplastic\/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia. 2021;35:3329\u201333.","journal-title":"Leukemia"},{"key":"2843_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.26828","volume":"98","author":"MM Patnaik","year":"2023","unstructured":"Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023;98:681\u20139.","journal-title":"Am J Hematol"},{"key":"2843_CR15","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/cancers13092120","volume":"13","author":"L Palomo","year":"2021","unstructured":"Palomo L, Acha P, Sol\u00e9 F. Genetic Aspects of Myelodysplastic\/Myeloproliferative Neoplasms. Cancers. 2021;13:2120.","journal-title":"Cancers"},{"issue":"5","key":"2843_CR16","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","volume":"103","author":"M Meggendorfer","year":"2018","unstructured":"Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T. The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms. Haematologica. 2018;103(5):e192\u2013e195. https:\/\/doi.org\/10.3324\/haematol.2017.183160.","journal-title":"Haematologica"},{"key":"2843_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ajh.24722","volume":"92","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, et al. Targeted next generation sequencing and identification of risk factors in W orld H ealth O rganization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92:542\u20138.","journal-title":"Am J Hematol"},{"key":"2843_CR18","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201317.","journal-title":"Blood"},{"key":"2843_CR19","doi-asserted-by":"publisher","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid 2022; 1. https:\/\/doi.org\/10.1056\/EVIDoa2200008.","DOI":"10.1056\/EVIDoa2200008"},{"key":"2843_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1182\/blood-2024-200104","volume":"144","author":"L Lanino","year":"2024","unstructured":"Lanino L, Hunter AM, Gagelmann N, Robin M, Sala C, Dall\u2019Olio D, et al. A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML). Blood. 2024;144:1003\u20131003.","journal-title":"Blood"},{"key":"2843_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha I, Greco R, Onida F, De La C\u00e1mara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696\u2013700.","journal-title":"Bone Marrow Transpl"},{"key":"2843_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11899-017-0411-0","volume":"12","author":"J Patterson-Fortin","year":"2017","unstructured":"Patterson-Fortin J, Moliterno AR. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. Curr Hematol Malig Rep. 2017;12:424\u201331.","journal-title":"Curr Hematol Malig Rep"},{"key":"2843_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ajh.24332","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016;91:492\u20138.","journal-title":"Am J Hematol"},{"key":"2843_CR24","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood.2023023476","volume":"143","author":"F Onida","year":"2024","unstructured":"Onida F, Gagelmann N, Chalandon Y, Kobbe G, Robin M, Symeonidis A, et al. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 2024;143:2227\u201344.","journal-title":"Blood"},{"key":"2843_CR25","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","volume":"56","author":"X Tong","year":"2015","unstructured":"Tong X, Li J, Zhou Z, Zheng D, Liu J, Su C. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leuk Lymphoma. 2015;56:1911\u20133.","journal-title":"Leuk Lymphoma"},{"key":"2843_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.19.00895","volume":"38","author":"K-HT Dao","year":"2020","unstructured":"Dao K-HT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2020;38:1006\u201318.","journal-title":"J Clin Oncol"},{"key":"2843_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","volume":"93","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol. 2018;93:277\u201385.","journal-title":"Am J Hematol"},{"key":"2843_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/labmed\/lmae018","volume":"55","author":"S Gupta","year":"2024","unstructured":"Gupta S, Courville EL. Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis. Lab Med. 2024;55:602\u20138.","journal-title":"Lab Med"},{"key":"2843_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/ejh.14430","volume":"115","author":"N Desai","year":"2025","unstructured":"Desai N, Rodriguez-Rodriguez S, Chen C, Moya TA, Al-Shaibani E, Novitzky-Basso I, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic\/Myeloproliferative Overlap Neoplasms. Eur J Haematol. 2025;115:142\u201352.","journal-title":"Eur J Haematol"},{"key":"2843_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.14619","volume":"177","author":"F Onida","year":"2017","unstructured":"Onida F, De Wreede LC, Van Biezen A, Eikema D-J, Byrne JL, Iori AP, et al. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2017;177:759\u201365.","journal-title":"Br J Haematol"},{"key":"2843_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ajh.27641","volume":"100","author":"H Itonaga","year":"2025","unstructured":"Itonaga H, Miyazaki Y, Kondo T, Shimazu Y, Aoki J, Kurosawa S, et al. Long-Term Survival After Allogeneic Hematopoietic Stem Cell Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia: A Nationwide Retrospective Study by Adult CML \/ MPN and MDS Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Am J Hematol. 2025;100:917\u201321.","journal-title":"Am J Hematol"},{"key":"2843_CR32","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.bbmt.2020.05.013","volume":"26","author":"S Kurosawa","year":"2020","unstructured":"Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic\/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2020;26:1607\u201311.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2843_CR33","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","volume":"35","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35:2445\u201359.","journal-title":"Leukemia"},{"key":"2843_CR34","first-page":"459.e1","volume":"29","author":"CJ Puzo","year":"2023","unstructured":"Puzo CJ, Tormey CA, Rinder HM, Siddon AJ. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transpl Cell Ther. 2023;29:459.e1\u2013459.e4.","journal-title":"Transpl Cell Ther"},{"key":"2843_CR35","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.23.01159","volume":"42","author":"M Tobiasson","year":"2024","unstructured":"Tobiasson M, Pandzic T, Illman J, Nilsson L, Westr\u00f6m S, Ejerblad E, et al. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2024;42:1378\u201390.","journal-title":"J Clin Oncol"},{"key":"2843_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa2408941","volume":"392","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, L\u00fcck C, et al. Clearance of Driver Mutations after Transplantation for Myelofibrosis. N Engl J Med. 2025;392:150\u201360.","journal-title":"N Engl J Med"},{"key":"2843_CR37","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood.2024025131","volume":"145","author":"C Gurnari","year":"2025","unstructured":"Gurnari C, Robin M, Ad\u00e8s L, Aljurf M, Almeida A, Duarte FB, et al. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood. 2025;145:1987\u20132001.","journal-title":"Blood"},{"key":"2843_CR38","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","volume":"379","author":"EJ Duncavage","year":"2018","unstructured":"Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, et al. Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med. 2018;379:1028\u201341.","journal-title":"N Engl J Med"},{"key":"2843_CR39","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","volume":"59","author":"A Sureda","year":"2024","unstructured":"Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, De La Fuente J, Ho A, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transpl. 2024;59:832\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2843_CR40","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood.2023021218","volume":"142","author":"N Kr\u00f6ger","year":"2023","unstructured":"Kr\u00f6ger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023;142:1683\u201396.","journal-title":"Blood"},{"key":"2843_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1365-2141.2008.07010.x","volume":"141","author":"SO Ciurea","year":"2008","unstructured":"Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol. 2008;141:80\u201383.","journal-title":"Br J Haematol"},{"key":"2843_CR42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206151","author":"DP McLornan","year":"2019","unstructured":"McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2018.206151.","journal-title":"Haematologica"},{"key":"2843_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08276.x","volume":"150","author":"M Robin","year":"2010","unstructured":"Robin M, Esp\u00e9rou H, de Latour RP, Petropoulou AD, Xhaard A, Ribaud P, et al. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. Br J Haematol. 2010;150:721\u20134.","journal-title":"Br J Haematol"},{"key":"2843_CR44","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","volume":"10","author":"N Polverelli","year":"2023","unstructured":"Polverelli N, Hern\u00e1ndez-Boluda JC, Czerw T, Barbui T, D\u2019Adda M, Deeg HJ, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10:e59\u2013e70.","journal-title":"Lancet Haematol"},{"key":"2843_CR45","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.bbmt.2014.05.016","volume":"20","author":"A Stasia","year":"2014","unstructured":"Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, et al. CD34 Selected Cells for the Treatment of Poor Graft Function after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2014;20:1440\u20133.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2843_CR46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bbmt.2013.11.034","volume":"20","author":"E Klyuchnikov","year":"2014","unstructured":"Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies. Biol Blood Marrow Transpl. 2014;20:382\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2843_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood.2019000358","volume":"135","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Chevret S, Ruggeri AL, Suarez F, Souchet L, Michonneau D, et al. Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial. Blood. 2020;135:227\u20139.","journal-title":"Blood"},{"key":"2843_CR48","first-page":"687.e1","volume":"29","author":"A Rampotas","year":"2023","unstructured":"Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, et al. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study. Transpl Cell Ther. 2023;29:687.e1\u2013687.e7.","journal-title":"Transpl Cell Ther"},{"key":"2843_CR49","doi-asserted-by":"publisher","first-page":"e921","DOI":"10.1097\/HS9.0000000000000921","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, et al. Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation. HemaSphere. 2023;7:e921.","journal-title":"HemaSphere"},{"key":"2843_CR50","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","volume":"11","author":"S Pagliuca","year":"2024","unstructured":"Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11:e448\u2013e458.","journal-title":"Lancet Haematol"},{"key":"2843_CR51","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u2013e74.","journal-title":"Lancet Haematol"},{"key":"2843_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-025-00652-5","volume":"14","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Lopez-Guerra M, Casta\u00f1o-D\u00edez S, Esteban D, Avenda\u00f1o A, Pomares H, et al. Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. Exp Hematol Oncol. 2025;14:61.","journal-title":"Exp Hematol Oncol"},{"key":"2843_CR53","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","volume":"100","author":"E Schuler","year":"2021","unstructured":"Schuler E, Wagner-Drouet E-M, Ajib S, Bug G, Crysandt M, Dressler S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents\u2014a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2021;100:959\u201368.","journal-title":"Ann Hematol"},{"key":"2843_CR54","doi-asserted-by":"publisher","first-page":"e642","DOI":"10.1016\/S2352-3026(24)00243-6","volume":"11","author":"M Robin","year":"2024","unstructured":"Robin M, Scheid C. Second allogeneic stem-cell transplantation or donor lymphocyte infusion in patients who relapse after transplantation? Lancet Haematol. 2024;11:e642\u2013e643.","journal-title":"Lancet Haematol"},{"key":"2843_CR55","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-021-01330-1","volume":"35","author":"A Renneville","year":"2021","unstructured":"Renneville A, Patnaik MM, Chan O, Padron E, Solary E. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia. 2021;35:2739\u201351.","journal-title":"Leukemia"},{"key":"2843_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2019001426","volume":"4","author":"DP McLornan","year":"2020","unstructured":"McLornan DP, Harrison CN. Guidance on changing therapy choice in myelofibrosis. Blood Adv. 2020;4:607\u201310.","journal-title":"Blood Adv"},{"key":"2843_CR57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet Lond Engl. 2021;398:803\u201316.","journal-title":"Lancet Lond Engl"},{"key":"2843_CR58","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Vannucchi AM, Passamonti F, Kremyanskaya M, Gotlib JR, Palmer JM, et al. A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood. 2019;134:557\u2013557.","journal-title":"Blood"},{"key":"2843_CR59","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","volume":"29","author":"HT Chifotides","year":"2020","unstructured":"Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020;29:525\u201336.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02843-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02843-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02843-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:02:42Z","timestamp":1778191362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02843-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02843-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests with regards to this consensus guideline.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}